Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment
- 28 February 2010
- journal article
- research article
- Published by Elsevier in Neurobiology of Aging
- Vol. 31 (3) , 357-367
- https://doi.org/10.1016/j.neurobiolaging.2008.03.027
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Clearance of amyloid-β by circulating lipoprotein receptorsNature Medicine, 2007
- Prediction of Alzheimer’s Disease Using the CSF Aβ42/Aβ40 Ratio in Patients with Mild Cognitive ImpairmentDementia and Geriatric Cognitive Disorders, 2007
- Alzheimer's diseasePublished by Elsevier ,2006
- Plasma levels of beta-amyloid (1–42) in Alzheimer's disease and mild cognitive impairmentNeurobiology of Aging, 2006
- Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up studyPublished by Elsevier ,2006
- The Goteborg MCI study: mild cognitive impairment is a heterogeneous conditionJournal of Neurology, Neurosurgery & Psychiatry, 2005
- Tau Suppression in a Neurodegenerative Mouse Model Improves Memory FunctionScience, 2005
- Standardization of measurement of β-amyloid(1-42)in cerebrospinal fluid and plasmaAmyloid, 2000
- High Levels of Circulating Aβ42 Are Sequestered by Plasma Proteins in Alzheimer's DiseaseBiochemical and Biophysical Research Communications, 1999
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984